Members of the ACCC IO Institute Executive Committee discuss why care coordination and communication among the IO team, other providers, and the patient is critical for effective delivery of immunotherapy for cancer. (features Mark Faries, MD; Sanjiv Agarwala, MD; and Niesha Griffith, MS, RPh, FASHP)
SARS-CoV-2 and the resulting respiratory tract infection COVID-19 has upended our society and forcefully changed the way we care for patients. Since the emergence of the virus in early 2020, there have been questions surrounding the risk posed to patients with a cancer diagnosis and the safety of anticancer therapies.
We explore how immunotherapy clinical trials have been affected by the pandemic and what cancer programs can do to safely and effectively administer clinical trials.
Download Article & Companion Guide